Our unique dual-targeted approach leverages an innovative proprietary platform to optimize the function of natural killer cells, thus maximizing cancer cell killing. We also focus on engineering strategies to enhance tumor homing and persistence in-vivo, and overcome exhaustion in the tumor microenvironment.
We are interested in working with leading academic centres, clinical institutions and industry partners to advance scientific understanding, preclinical and clinical evaluation, cell engineering and manufacturing capabilities to drive innovations in the field of NK cell therapies.
- USPTO Grants ONK Therapeutics’ Foundational Patent for CISH Knockout in NK Cells for Use in Cancer Therapies 9 September 2021
- ONK Therapeutics’ CSO Prof. M O’Dwyer and his Academic Group Present New Data Showing the Benefit of Knocking Out the Inhibitory Receptor CD96 on Human NK Cells in the Context of Multiple Myeloma at EHA 2021 11 June 2021
ONK Therapeutics featured in the Spring Edition of Nature BioPharma Dealmaker
Maximizing synergy and mitigating resistance: novel dual-targeted natural killer cell therapies for cancer